SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC initially responds very well to platinum-based chemotherapy, it eventually recurs and at recurrence is nearly universally resistant to therapy. In light of the recent advances in understanding regarding the biology of SCLC, we review findings related to SCLC chemotherapy resistance. We discuss the potential clinical implications of recent preclinical discoveries in altered signaling pathways, transcriptional landscapes, metabolic vulnerabilities, and the tumor microenvironment.

Original languageEnglish
Pages (from-to)2002-2015
Number of pages14
JournalJournal of Thoracic Oncology
Issue number12
StatePublished - Dec 2021


  • Chemoresistance
  • Chemotherapy
  • Resistance
  • SCLC
  • Small cell lung cancer


Dive into the research topics of 'Overcoming Chemotherapy Resistance in SCLC'. Together they form a unique fingerprint.

Cite this